Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMEGA: Oral vs IV Methylprednisolone in MS Exacerbations
NCT00418145Phase 3Terminated
- Sponsor
- Fred Lublin
- Start
- Sep 2003
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone injection in multiple sclerosis (MS) (2 arms), sponsored by Fred Lublin. Primary endpoint: Expanded Disability Status Scale Mean Recovery at 90 days. Started Sep 2003; status: terminated.
02
Drugs
methylprednisolone injection
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00418145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418145.